Moreover, tumour biopsies of patients with head and neck cancer exhibited the elevated CRL substrates CDT1 and NRF2 after MLN4924 treatment, indicating MLN4924 as an effective neddylation inhibitor and a potent clinical strategy for the treatment of HNSCC.23 However, the underlying mechanisms of anti‐HNSCC effects of MLN4924 remain elusive. Here, CDT1 is linked to head and neck squamous cell carcinoma.